Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OCGN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Whole-Virion Inactivated SARS-CoV-2 Vaccine… | COVID-19 | Phase 2/3 · NCT05258669 | Unknown |
| OCU410 | Dry Age-related Macular Degeneration | Phase 3 · NCT07770828 | Recruiting |
| OCU410ST | Stargardt Disease | Phase 2/3 · NCT05956626 | Active not recruiting |
| Brimonidine | Dry Eye | Phase 2 · NCT03418727 | Completed |
| Brimonidine Mono Therapy | Dry Eye | Phase 2 · NCT03418727 | Completed |
| Corticosteroid-containing Eye Drop | Dry Eye | Phase 2 · NCT03418727 | Completed |
| OCU400 | Retinitis Pigmentosa | Phase 1/2 · NCT05203939 | Active not recruiting |
| OCU400 Med Dose | Retinitis Pigmentosa | Phase 1/2 · NCT05203939 | Active not recruiting |
| OCU400 Second Eye Dosing | Retinitis Pigmentosa | Phase 1/2 · NCT05203939 | Active not recruiting |
| sodium carboxymethylcellulose | Dry Eye | Phase 2 · NCT03418727 | Completed |
| OCU200 | Center Involved Diabetic Macular Edema | Phase 1 · NCT05802329 | Recruiting |
Also used in these trials (approved or third-party drugs, not OCGN's own candidates): Brimonidine Tartrate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OCGN holds $84.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $14M/quarter from operations, an estimated runway of 18.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 33 · Moderate
After evaluating these conditions and management’s plans, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OCGN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 26,952,492 | 7.94% | 2026-06-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 21,469,307 | 6.33% | 2026-06-30 |
| Millennium Management LLC | 5%+ holder (13G) | 17,074,584 | 5.03% | 2026-04-09 |
| Vanguard Capital Management LLC | Institution (13F) | 14,140,436 | 4.17% | 2026-09-30 |
| UBS Group AG | Institution (13F) | 9,555,521 | 2.82% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 8,662,430 | 2.55% | 2026-09-30 |
| RTW Investments LP | Institution (13F) | 6,666,666 | 1.96% | 2026-09-30 |
| Shankar Musunuri Chief Executive Officer, Director · +5.44M options |
Insider | 5,049,241 | 1.49% | 2026-10-09 |
| Two Sigma Investments, LP | Institution (13F) | 3,941,300 | 1.16% | 2026-09-30 |
| Ikarian Capital, LLC | Institution (13F) | 3,562,972 | 1.05% | 2026-09-30 |
| GMT Capital Corp | Institution (13F) | 3,505,398 | 1.03% | 2026-09-30 |
| Hennion & Walsh Asset Management, Inc. | Institution (13F) | 3,385,645 | 1.00% | 2026-09-30 |
Share count 339,306,603 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-09 filed 2026-10-13 |
Musunuri Shankar |
Sale (S) | 468,727 | $0.95 | 4,018,470 |
| 2026-10-09 filed 2026-10-13 |
Musunuri Shankar |
Sale (S) | 57,264 | $0.95 | 1,030,771 |
| 2026-09-09 filed 2026-09-11 |
Musunuri Shankar |
Sale (S) | 468,727 | $1.12 | 4,487,197 |
| 2026-09-09 filed 2026-09-11 |
Musunuri Shankar |
Sale (S) | 57,264 | $1.12 | 1,088,035 |
| 2026-06-15 filed 2026-06-17 |
Johnson-Greene Treerita Essalima |
Purchase (P) | 21,000 | $1.23 | 521,000 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCGN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →